文献速递血液净化与透析

维持性血液透析患者中β受体阻滞剂的透析清除性:一项随机临床试验

β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-03-08

该研究纳入8例高通量血液透析患者,采用开放标签、药代动力学、四周期交叉设计,随机顺序单次给予阿替洛尔、美托洛尔、比索洛尔和卡维地洛,测定血浆和透析液药物浓度以评估透析清除性。结果表明阿替洛尔和美托洛尔被透析广泛清除,卡维地洛透析清除可忽略,而比索洛尔也可透析清除,与既往文献估计相反。

要点

  • 阿替洛尔和美托洛尔经高通量血液透析广泛清除
  • 卡维地洛的透析清除可忽略不计
  • 比索洛尔也可被透析清除,与既往文献估计相反

核心结论

  • 阿替洛尔和美托洛尔经血液透析广泛清除,卡维地洛透析清除可忽略。
  • 比索洛尔也可透析清除,与基于既往文献的估计相反。

研究设计与样本

  • 开放标签、药代动力学、四周期交叉试验,纳入8例维持性血液透析患者。
  • 单次剂量阿替洛尔、美托洛尔、比索洛尔和卡维地洛按随机顺序在不同天给药。

主要发现

  • 回收清除率法测得阿替洛尔、美托洛尔、比索洛尔和卡维地洛的透析清除率分别为72、87、44和0.2 ml/min(P<0.001)。
  • 动静脉差值法测得上述药物透析清除率分别为167、114、96和24 ml/min(P<0.001)。

临床怎么用

  • 高通量血液透析患者使用阿替洛尔或美托洛尔时需考虑透析清除对血药浓度的影响。
  • 卡维地洛透析清除可忽略,透析后可能无需补充剂量。
  • 比索洛尔可被透析清除,应关注透析后的药物补充问题。

局限性

  • 样本量仅8例,结果外推需谨慎。
  • 仅评估单次给药后的药代动力学,未涉及长期用药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: There is a paucity of data available to describe drug dialyzability. Of the available information, most was obtained before implementation of modern hemodialysis membranes. Our study characterized dialyzability of the most commonly prescribed β-blockers in patients undergoing high-flux hemodialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients on hemodialysis (n=8) were recruited to an open label, pharmacokinetic, four-way crossover trial. Single doses of atenolol, metoprolol, bisoprolol, and carvedilol were administered on separate days in random order to each patient. Plasma and dialysate drug concentrations were measured, and dialyzability was determined by the recovery clearance and arterial venous difference methods. RESULTS: Using the recovery clearance method, the dialytic clearance values for atenolol, metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P<0.001). Applying the arterial venous difference method, the dialytic clearance values of atenolol, metoprolol, bisoprolol, and carvedilol were 167, 114, 96, and 24 ml/min, respectively (P<0.001). CONCLUSIONS: Atenolol and metoprolol are extensively cleared by hemodialysis compared with the negligible dialytic clearance of carvedilol. Contrary to estimates of dialyzability on the basis of previous literature, our data indicate that bisoprolol is also dialyzable. This finding highlights the importance of conducting dialyzability studies to definitively characterize drug dialytic clearance.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Tieu A, Velenosi TJ, Kucey AS, et al. β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. Clin J Am Soc Nephrol. 2018. PMID: 29519953. doi:10.2215/CJN.07470717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。